Apollomics Inc.
APLMInvestment snapshot
Positive
1
BUY / PASS
Neutral / negative
2 / 13
NEUTRAL / FAIL
Median fair value
$7.56
-57.2% vs price
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | FAIL | FAIL | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Margin of Safety | N/A | N/A | N/A | -133.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Market data at 2026-11-01 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Market data at 2026-11-01 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-03 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-03 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 1✗ 34▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)0/6 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)0/6 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-762.9%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-1107.3%✗Lynch> 15%EBIT / Enterprise Value-127.9%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-127.9%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-411.19%✗PiotroskiROA > 0ROA Change YoY-311.63% -> -411.19% (delta: -99.57%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-219.45%, ROA=-411.19%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY✗PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity-1107.3%✗Dreman> 12%Margin of SafetyP/B=3.7x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-762.9% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue✗Ackman>= 15%Net Income / Shareholders Equity-1107.3%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-104.50%; #5404/6340 (top 85.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-1107.28%; #5169/5226 (top 98.9%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-1.2320; #5332/5884 (top 90.6%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/5 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Valuation0% pass✗ 28▾
All 13 investors flag APLM's valuation
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio3.7x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-127.9%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-127.9%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share3.7x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation Reasonableness✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-55.8%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=3.7x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low450% of trailing low ($3.93)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-104.50%; #5404/6340 (top 85.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.0944; #4780/6449 (top 74.1%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share5.77x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.0000; #5080/5247 (top 96.8%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-55.82%; #3888/4519 (top 86.0%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+24.95%; #1170/6202 (top 18.9%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy✗BuffettPositive and growingFCF Positive and Growing$-28.8M✗LynchPositive and growingOperating Cash Flow$-28.7M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-219.45%, ROA=-411.19%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-55.8%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/5 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-159.5%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/5 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-28.8M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-55.82%; #3888/4519 (top 86.0%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthN/A (no inventory)✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth✗Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✗ 11▾
All 8 investors flag APLM's efficiency
Current Ratio1.39✗Graham>= 2.0ROIC (3-5 yr avg)✗Buffett> 10%ROIC - WACC✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY2.95 -> 1.39✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.00x -> 0.00x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities1.39✗Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2022: ROIC=unavailable; FY2023: ROIC=unavailable; FY2024: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years - Verdicts7% pass✓ 1✗ 13▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✓MungerPASS (2/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (2/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage50% pass✓ 9✗ 6▾
6 of 12 pass — Graham, Buffett, Lynch +3 more object
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.00, IC: -298.4x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0✓Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities1.39✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-298.4x, D/EBITDA=0.0x (no debt)✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)✓AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2024
Share retirement not available for this company.
- Buybacks
- —
- Dividends
- $0
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
| Metric | FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
| FY 2020Sources
|
|---|---|---|---|---|---|
| Market Cap | $51.5Mcurrent | $6.0Best. | $408.0Best. | $401.6Best. | $358.6Best. |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -- | -- | $976.0K | -- | -- |
| Net Income | -$53.9M↑69% | -$172.6M↑28% | -$240.8M↓154% | -$94.8M↓27% | -$74.8M |
| EPS (Diluted) | $-52.80↓2176% | $-2.32↓274% | $-0.62↓170% | $-0.23↓10% | $-0.21 |
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| ROE | -1107.3%↓165% | -418.6%↓879% | 53.7%↑21% | 44.5%↓24% | 58.5% |
| Total Debt | $0↓100% | $425.0K↓57% | $991.0K↓4% | $1.0M | -- |
| Shareholders' Equity | $4.9M↓88% | $41.2M↑109% | -$448.1M↓111% | -$212.9M↓66% | -$127.9M |
| Current Ratio | 1.39↓53% | 2.95↓35% | 4.51↓38% | 7.33 | — |
| Debt / Equity | 0.00↓100% | 0.01↑566% | -0.00↑55% | -0.00 | — |
| Operating Cash Flow | -$28.7M↑33% | -$43.2M↓1% | -$42.8M↑1% | -$43.3M↓21% | -$35.7M |
| Free Cash Flow | -$28.8M↑33% | -$43.2M | -$43.2M | -$43.4M↓21% | -$35.8M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
APLM vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |